UroGen Pharma's ZUSDURI is positioned for accelerated adoption following a permanent J-Code in 2026. Read more on URGN stock and why it is a Buy.

A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.

Prostate cancer researchers Urine cytology after an initial TURBT predicted risk for a second TURBT one month later. The following article features coverage from the American Urological Association ...

A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Background: Frail and elderly patients ...

PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay between first sign and diagnosis can mean the difference between a ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Bladder cancer is the seventh most common cancer in men, with nearly 400,000 cases diagnosed per year. However, despite the use of transurethral resection of the bladder tumor (TURBT), a large number ...